Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.02 – $3.23
7% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $783.1M | $844.8M | $663.6M | $565.0M | $624.3M | $638.8M | $590.0M | $25.9M |
| Cost of revenue | $171.8M | $105.6M | $65.6M | $78.9M | $102.6M | $88.9M | $72.1M | $81.3M |
| Gross profit | $611.3M | $739.2M | $598.0M | $486.1M | $521.7M | $549.9M | $517.9M | −$55.4M |
| Gross margin | 78.1% | 87.5% | 90.1% | 86.0% | 83.6% | 86.1% | 87.8% | -213.5% |
| R&D | $166.8M | $181.3M | $224.9M | $272.3M | $318.0M | $303.1M | $340.0M | $176.6M |
| Operating income | $95.8M | $231.2M | −$22.1M | −$224.9M | −$214.2M | −$109.5M | −$140.3M | −$346.0M |
| EBITDA | $110.3M | $288.4M | $16.8M | −$141.3M | −$73.9M | −$22.0M | $13.0M | −$285.2M |
| Net income | $137.9M | $219.1M | −$84.4M | −$223.5M | −$177.6M | −$128.3M | −$203.0M | −$129.5M |
| Net margin | 17.6% | 25.9% | -12.7% | -39.6% | -28.4% | -20.1% | -34.4% | -499.2% |
| EPS (diluted) | 3.93 | 6.20 | -2.45 | -6.51 | -5.17 | -3.73 | -5.89 | -3.74 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $26M | $-8.98 | $-8.98–$-8.98 | 1 |
| 2027 | $27M | $-7.17 | $-7.17–$-7.17 | 1 |
| 2028 | $31M | $-7.70 | $-7.70–$-7.70 | 1 |
Forward consensus · source: Financial Modeling Prep
OREXO AB ORD
No one on the platform currently holds ORXOF.
No tracked institution reports a position in ORXOF as of their last filing.
No one on the platform has traded ORXOF yet.
| $230M |
| — |
| JUSHFJushi Holdings Inc. | $0.48 | -1.03% | $96M | — |
| LOVFFCannara Biotech Inc. | $1.21 | +5.52% | $120M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 0.1× historical median P/S.
Fair value ≈ $1.83 · price $2.10 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.